Results 1 to 10 of about 3,388,118 (388)

Acknowledgment to Reviewers of Biologics in 2021

Biologics, 2022
Rigorous peer-reviews are the basis of high-quality academic publishing [...]
Biologics Editorial Office
doaj   +1 more source

EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023.

Rhinology, 2023
Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with a significant impact on the quality of life (QoL). It is typically characterized by a type 2 inflammatory reaction and by comorbidities such as asthma, allergies and ...
W. Fokkens, A. Viskens, Vibeke Backer, D. Conti, E. Corso, P. Gevaert, G. Scadding, Martin Wagemann, Manuel Bernal - Sprekelsen, A. Chaker, E. Heffler, Joseph K. Han, E. V. Staeyen, C. Hopkins, J. Mullol, A. Peters, S. Reitsma, B. Senior, P. Hellings   +18 more
semanticscholar   +1 more source

Assessing developability early in the discovery process for novel biologics

mAbs, 2023
Beyond potency, a good developability profile is a key attribute of a biological drug. Selecting and screening for such attributes early in the drug development process can save resources and avoid costly late-stage failures.
M. Fernández-Quintero, Anne Ljungars, Franz Waibl, V. Greiff, J. Andersen, Torelif T Gjølberg, T. Jenkins, B. Voldborg, L. M. Grav, Sandeep Kumar, G. Georges, H. Kettenberger, K. Liedl, Peter M. Tessier, J. McCafferty, A. H. Laustsen   +15 more
semanticscholar   +1 more source

Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients

Allergy. European Journal of Allergy and Clinical Immunology, 2023
Asthma remission has emerged as a potential treatment goal. This study evaluated the effectiveness of two biologics (mepolizumab/omalizumab) in achieving asthma remission.
D. Thomas, V. McDonald, S. Stevens, E. Harvey, M. Baraket, Philip Bardin, J. Bowden, S. Bowler, Jimmy Chien, L. Chung, A. Gillman, M. Hew, S. Hodge, Alan James, C. Jenkins, C. Katelaris, G. Katsoulotos, D. Langton, Joy Lee, G. Marks, M. Peters, N. Radhakrishna, P. Reynolds, J. Rimmer, P. Sivakumaran, J. Upham, P. Wark, Ian A Yang, P. Gibson   +28 more
semanticscholar   +1 more source

Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis

JAMA dermatology, 2023
This cohort study examines which biologic drug classes and factors are associated with risk of paradoxical eczema in patients with psoriasis treated with biologics.
A. Al-Janabi, Oras A Alabas, Zenas Z N Yiu, A. Foulkes, S. Eyre, Adnan R. Khan, N. Reynolds, Catherine H. Smith, C. Griffiths, R. B. Warren   +9 more
semanticscholar   +1 more source

Biologics and airway remodeling in severe asthma

Allergy. European Journal of Allergy and Clinical Immunology, 2022
Asthma is a chronic inflammatory airway disease resulting in airflow obstruction, which in part can become irreversible to conventional therapies, defining the concept of airway remodeling.
G. Varricchi, S. Ferri, J. Pepys, R. Poto, G. Spadaro, E. Nappi, G. Paoletti, J. C. Virchow, E. Heffler, W. Canonica   +9 more
semanticscholar   +1 more source

Biologics for severe asthma—Which, when and why?

Respirology (Carlton South. Print), 2023
Asthma is a common chronic inflammatory condition of the airways that affects about 350 million people globally. In 5%–10% of individuals, it is severe, with considerable morbidity and high health care utilization.
Peer Ameen Shah, C. Brightling
semanticscholar   +1 more source

Green Biologics: Harnessing the Power of Plants to Produce Pharmaceuticals

International Journal of Molecular Sciences, 2023
Plants are increasingly used for the production of high-quality biological molecules for use as pharmaceuticals and biomaterials in industry. Plants have proved that they can produce life-saving therapeutic proteins (Elelyso™—Gaucher’s disease treatment,
G. Zahmanova, Alaa A. A. Aljabali, Katerina H. Takova, George Minkov, M. Tambuwala, Ivan Minkov, G. Lomonossoff   +6 more
semanticscholar   +1 more source

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

OncoImmunology, 2021
Anti-programmed cell death-1 (PD-1)/PD-ligand-1 (PD-L1) treatments are effective in a fraction of patients with advanced malignancies. However, the majority of patients do not respond to it.
Haiping Jiang, Haiqing Ni, Pan Zhang, Xiaoli Guo, Min Wu, Haoran Shen, Jie Wang, Weiwei Wu, Zhihai Wu, Jiazheng Ding, Rong Tang, Shuaixiang Zhou, Bingliang Chen, Michael Yu, Hua Jing, Junjian Liu   +15 more
doaj   +1 more source

Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity

Nature Communications, 2021
The toxicity arising from generalised stimulation of T cells restricts applicability of CD137 agonists in cancer immune therapy. Here authors show that a bispecific antibody blocking PD-1 while activating CD137 efficiently restricts T cell activation to ...
Yunqian Qiao, Yangmin Qiu, Jie Ding, Nana Luo, Hao Wang, Xiaomin Ling, Jiya Sun, Zhihai Wu, Yisen Wang, Yanpeng Liu, Feifei Guo, Ta Sun, Wanwan Shen, Min Zhang, Dongdong Wu, Bingliang Chen, Wei Xu, Xuan Wang   +17 more
doaj   +1 more source